8th August 2022
It’s that time of the year again. It’s Diabetes Tech & Talk 2022. it is that time of the year where we get to interact and intermingle with colleagues – GPs, endocrinologists, diabetes educators and researchers.
We are exploring Innovation and Integration in Diabetes Clinical Care, Self-management and Prevention this year. We are extremely privileged that this year’s key note speaker is Professor Dianna Magliano.…
30th July 2022, Spectrum Medical Imaging
Up to 31%-69% of COVID-19 survivors will experience long COVID symptoms after initial recovery from SARS-CoV-2 infection [1, 2]. While the initial symptoms of long COVID symptoms include fatigue (29%), muscle pain, palpitations, cognitive impairment (28%), dyspnea (21%), anxiety (27%), chest pain, and arthralgia (18%) [3], in patients experiencing long covid symptoms, fatigue is most prevalent (51%), followed by dyspnoea (35%), arthralgia (25%) and concentration difficulties (25%).…
30th July 2022, Dr Chee L Khoo
I recently came across a trial comparing arthroscopic partial meniscectomy (APM) with physiotherapy (PT) in the management of medial meniscal tears in older patients. Older patients here mean patients that are older than 45 years who are supposed to have degenerated menisci. Now, meniscal tears (usually medial but sometimes can be lateral meniscal tear) in younger patients often require surgical intervention but in older patients, surgery is not necessarily better than conservative physiotherapy.…
29th July 2022, Dr Chee L Khoo
12 months ago, at GPVoice, we announced the arrival of drug LY3298176, which now has a name, tirzepatide, as the first in its class of “twincretins” in the management of type 2 diabetes. We briefly explored the 4 Phase 3 trials looking at the efficacy and safety of trizepatide in comparison with placebo, semaglutide, insulin degludec and insulin glargine.…
13th July 2022, Dr Chee L Khoo
In the last issue of GPVoice, we looked at the up-to-date guidelines in the management of dyslipidaemia in primary and secondary prevention. We looked at how complex those guidelines are. We also touched on the fact not all the evidence behind the guidelines is Level A evidence. The PCSK9 inhibitors, in particular, are a relatively new class of lipid lowering agents and the data is still coming in.…
13th July 2022, Dr Chee L Khoo
Have you noticed we don’t hear about congestive cardiac failure (CCF) anymore? Its’ just plain heart failure (HF) now. It makes sense because not all heart failures are congestive in nature. Of course, you are aware of the new terms – heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).…
26th June 2022, Dr Chee L Khoo
I was recently tasked with preparing a lecture on the current guidelines for lipid management in patients with diabetes. I thought it was quite straight forward. We have known for some years now that the targets are tighter than patients without diabetes. Thus, it can’t be that hard. As I looked into national and international guidelines, they started to get more and more complicated.…
26th June 2022, Dr Chee L Khoo
Tell me, what time did you get home last night? When did you last work a Saturday or a Sunday? When did you last truly spend time with the whole family? I bet you still fly economy class when you last went overseas. I am not telling you anything you don’t already know. Our rebates have not gone up for > 20 years.…
13th June 2022, Dr Chee L Khoo
Fenofibrate is a commonly-used lipid lowering agent. In particular, it is recommended for patients with high triglycerides. Two previous studies have demonstrated that fenofibrate reduces the progression of diabetic retinopathy (DR) in patients who already have DR. Despite the benefits of fenofibrate, we don’t see recommendations for its use featured prominently in guidelines.…
12th June 2022, Dr Chee L Khoo
Non-alcoholic fatty liver disease (NAFLD) is the most common liver condition in the western world. A significant proportion of these patients developed inflammation and progressed to non-alcoholic steato-hepatitis (NASH). Further and persistent inflammation can lead to cirrhosis and ultimately, to liver failure or liver cancer. Management till recently is primarily targeted towards lifestyle measures to reduce liver fat.…
11th June 2022, Dr Chee L Khoo
Diabetic retinopathy (DR) will affect at least 1 in 3 of our patients with diabetes. Did you know that DR is the leading cause of irreversible blindness in women of reproductive age? Further, the progression continues up to 12 months postpartum. Type 1 diabetes is on the increase and young type 2 diabetes is definitely on the rise.…
31st May 2022, Spectrum Medical Imaging
We know that different women have different breast types. Some breasts are more dense than others. Some breasts have more adipose tissues than others. Obviously, with age, those features will change. Thus, the ideal imaging techniques will be different and will depend on the breast type, the age and the underlying risk of the woman, amongst many other things.…